Nintedanib - BIBF-1120

Based on 632 publications in PubMed 9 10 632

Axon 2648

CAS [656247-17-5]

MF C31H33N5O4
MW 539.62

  • Purity: 100%
  • Soluble in 0.1N HCl(aq) and DMSO

Nintedanib

Description

Orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities that simultaneously targets VEGFR1-3 (IC50 values 34 nM, 21 nM, and 13 nM, resp.), PDGFRα and β (IC50 values 59 and 65 nM), and FGFR1-3 (IC50 values 69 nM, 37 nM, and 108 nM, resp). In addition, BIBF1120 also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (IC50 values 156 nM, 16 nM, 195 nM, and 26 nM, resp.).

KEYWORDS: Nintedanib | supplier | RTK inhibitor | Angiokinase inhibitor | BIBF-1120 | BIBF1120 | Intedanib | CAS [656247-17-5] - [656247-18-6] | PDGF-FGF-VEGF | PDGFR | FGFR | VEGFR | Receptor tyrosine kinase | Src | Lck | Lyn | FLT-3 | antiangiogenic | antineoplastic | antitumor

Order
Size Unit Price Stock
10 mg €75.00 In Stock
50 mg €150.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...